MHC-associated Peptide Proteomics (MAPPS) Assay

MAPPS Assay

Immunogenicity generally refers to the ability of a therapeutic product to elicit an immune response in the body, such as the production of anti-drug antibodies (ADAs). In recent years, methods for MHC-associated peptide proteomics (MAPPS) have been developed for the identification of peptide sequences derived from therapeutic proteins. Creative Biolabs provides the MAPPS assay to help you identify peptides processed and presented by MHC during your research.

Our Service

Creative Biolabs offers MAPPS assays that allow the identification of peptides naturally processed and presented by MHC. The MAPPS assay can be used to determine immunoassay epitopes on the one hand, and directly identify peptides presented by antigen-presenting cells to T cells on the other. In detail, MAPPS assay resolves protein epitopes presented to T cells by HLA molecules and identifies peptides by the methods of HLA-peptide complex extraction, peptide elution, and sequencing mass spectrometry to identify peptide epitopes.

Fig.1 Assay procedure of MAPPS. (Karle, 2020)

The MAPPS assay consists of multiple steps:
Step 1: Monocytes are isolated from the buffy coat and differentiate into DCs in vitro.
Step 2: The DC load subsequently has the blood pressure of interest.
Step 3: After cleavage, HLA class II molecules are isolated by immunocapture, the eluted peptides are analyzed by LC-MS.
Step 4: The results were searched in the database to identify the peptides.

Fig.1 Assay procedure of MAPPS.¹

Published Data

Following are some published data displayed that refer to MAPPS assay:

Fig.2 Infliximab peptide sequence identified using MAPPS.²

Fig.3 Mass chromatograms of typical TIC and peptide samples from MAPPS.²

Fig.4 Number of peptides identified in each cluster of infliximab obtained from different numbers of DCs using MAPPS.²

Applications of MAPPS Assay

Discovery and characterization of epitope
Identify the underlying cause of clinical immunogenicity
Confirm the predicted sequence for characterization and further improvements
Sort similar protein variants and support candidate selection
Generate data to support a regulatory submission

Benefit and Prospect

Automated cell isolation process
Streamlined peptide isolation process
Automated LC-MS sample loading
Dual column switching
Data analysis is efficient and accurate

Frequently-Asked Questions

Q1: What are the differences between in silico Algorithms and MAPPS?

A: Compared to in silico approaches, MAPPS assays are able to identify relevant peptides naturally processed and presented by primary specialist APCs. Moreover, MAPP data also can provide an opportunity to train new HLA Class II combined prediction algorithms and may also help identify sequence fragments that are conserved in antibodies.

Q2: Can antigen presentation be detected in cryopreserved cells?

A: Yes. We have the technicians and equipment to extract MHC peptide complexes from frozen cells for testing.

Professional consultation provides guidance before, during, and after the project, please contact us for your tailored solution.

References

Karle, A.C. Applying MAPPs assays to assess drug immunogenicity. Front Immunol. 2020.
Sekiguchi, N.; et al. MHC-associated peptide proteomics enabling highly sensitive detection of immunogenic sequences for the development of therapeutic antibodies with low immunogenicity. MAbs. 2018, 10(8): 1168-1181.

For Research Use Only | Not For Clinical Use

Resources

Download our brochure

Online Inquiry